WO2012100734A1 - Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma - Google Patents

Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma Download PDF

Info

Publication number
WO2012100734A1
WO2012100734A1 PCT/CN2012/070678 CN2012070678W WO2012100734A1 WO 2012100734 A1 WO2012100734 A1 WO 2012100734A1 CN 2012070678 W CN2012070678 W CN 2012070678W WO 2012100734 A1 WO2012100734 A1 WO 2012100734A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
thiazol
added
chlorophenyl
compound
Prior art date
Application number
PCT/CN2012/070678
Other languages
English (en)
Inventor
Yonghui Wang
Ting Yang
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2012100734A1 publication Critical patent/WO2012100734A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Definitions

  • the present invention relates to novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
  • RORy retinoid-related orphan receptor gamma
  • RORs Retinoid-related orphan receptors
  • the ROR family consists of three members, ROR alpha (RORa), ROR beta (ROR0) and ROR gamma (RORy), each encoded by a separate gene (RORA, RORB and RORC, respectively).
  • RORs contain four principal domains shared by the majority of nuclear receptors: an N-terminal A/B domain, a DNA-binding domain, a hinge domain, and a ligand binding domain. Each ROR gene generates several isoforms which differ only in their N-terminal A B domain. Two isoforms of RORy have been identified: RORyl and RORyt (also known as RORy2).
  • RORy is a term used to describe both RORyl and/or RORyt.
  • Thl7 cells are a subset of T helper cells which produce IL- 17 and other proinflammatory cytokines. Thl7 cells have been shown to have key functions in several mouse autoimmune disease models including experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA).
  • EAE experimental autoimmune encephalomyelitis
  • CIA collagen-induced arthritis
  • Thl7 cells or their products have been shown to be associated with the pathology of a variety of human inflammatory and autoimmune disorders including multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease and asthma (Jetten (2009) Nucl. Recept. Signal 7: e003; Manel et al. (2008) Nat. Immunol. 9:641-649).
  • the pathogenesis of chronic autoimmune diseases including multiple sclerosis and rheumatoid arthritis arises from the break in tolerance towards self-antigens and the development of auto-aggressive effector T cells infiltrating the target tissues.
  • Thl7 cells are one of the important drivers of the inflammatory process in tissue-specific autoimmunity (Steinman (2008) J. Exp. Med. 205: 1517- 1522; Leung et al. (2010) Cell. Mol. Immunol. 7: 182-189). There is evidence that Th 17 cells are activated during the disease process and are responsible for recruiting other inflammatory cells types, especially neutrophils, to mediate pathology in the target tissues ( orn et al. (2009) Annu. Rev.
  • RORyt plays a critical role in the pathogenic responses of Thl7 cells (Ivanov et al. (2006) Cell 126: 1121-1133). RORyt deficient mice show very little Thl7 cells. In addition, RORyt deficiency resulted in amelioration of EAE. Further support for the role of RORyt in the pathogensis of autoimmune or inflammatory diseases can be found in the following references: Jetten & Joo (2006) Adv.Dev.Biol. 16:313-355; Meier et al. (2007) Immunity 26:643-654; Aloisi & Pujol-Borrell (2006) Nat. Rev. Immunol. 6:205-217; Jager et al. (2009) J. Immunol. 183:7169-7177; Serafmi et al. (2004) Brain Pathol.14: 164-174; Magliozzi et al. (2007) Brain 130: 1089-1104; Barnes (2008)
  • the invention is directed to novel RORy modulators and their use in the treatment of diseases mediated by RORy. Specifically, the invention is directed to compounds according to Formula I.
  • this invention provides for the use of the compounds of Formula I for the treatment of diseases mediated by RORy.
  • diseases include autoimmune or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease and asthma.
  • the invention is directed to methods of treating such diseases.
  • Alkyl refers to a monovalent saturated hydrocarbon chain having the specified number of member atoms.
  • C1-C6 alkyl refers to an alkyl group having from 1 to 6 member atoms.
  • Alkyl groups may be optionally substituted with one or more substituent as defined herein.
  • Alkyl groups may be straight or branched.
  • branched alkyl groups have one, two, or three branches
  • Alkyl includes methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, and t-butyl), pentyl (n-pentyl, isopentyl, and neopentyl), and hexyl.
  • Alkoxy refers to the group -O-R where R is alkyl having the specified number of member atoms. Alkoxy includes methoxy, ethoxy and propoxy.
  • Enantiomerically enriched refers to products whose enantiomeric excess is greater than zero.
  • enantiomerically enriched refers to products whose enantiomeric excess is greater than 50% ee, greater than 75% ee.and greater than 90% ee.
  • Enantiomeric excess or "ee” is the excess of one enantiomer over the other expressed as a percentage. As a result, since both enantiomers are present in equal amounts in a racemic mixture, the enantiomeric excess is zero (0% ee). However, if one enantiomer was enriched such that it constitutes 95% of the product, then the enantiomeric excess would be 90% ee (the amount of the enriched enantiomer, 95%, minus the amount of the other enantiomer, 5%).
  • Enantiomerically pure refers to products whose enantiomeric excess is 99% ee or greater.
  • Half-life refers to the time required for half of a quantity of a substance to be converted to another chemically distinct species in vitro or in vivo.
  • Halo refers to the halogen radicals fluoro, chloro, bromo, and iodo.
  • Heteroatom refers to a nitrogen, sulphur, or oxygen atom.
  • Member atoms refers to the atom or atoms that form a chain or ring. Where more than one member atom is present in a chain and within a ring, each member atom is covalently bound to an adjacent member atom in the chain or ring. Atoms that make up a substituent group on a chain or ring are not member atoms in the chain or ring.
  • Optionally substituted indicates that a group, such as alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heteroaryl, may be unsubstituted, or the group may be substituted with one or more substituent as defined.
  • RORy refers to all isoforms encoded by the RORC gene which include ROR l and RORyt.
  • RORy modulator refers to a chemical compound that inhibits, either directly or indirectly, the activity of RORy.
  • RORy modulators include antagonists and inverse agonists of RORy.
  • “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Substituted in reference to a group indicates that one or more hydrogen atom attached to a member atom within the group is replaced with a substituent selected from the group of defined substituents. It should be understood that the term “substituted” includes the implicit provision that such substitution be in accordance with the permitted valence of the substituted atom and the substituent and that the substitution results in a stable compound (i.e. one that does not spontaneously undergo transformation such as by rearrangement, cyclization, or elimination and that is sufficiently robust to survive isolation from a reaction mixture). When it is stated that a group may contain one or more substituent, one or more (as appropriate) member atom within the group may be substituted. In addition, a single member atom within the group may be substituted with more than one substituent as long as such substitution is in accordance with the permitted valence of the atom. Suitable substituents are defined herein for each substituted or optionally substituted group.
  • the present invention provides, in a first aspect, a compound of Formula I or a
  • X is selected from the group consisting of:
  • Ra is H or C1-C6 alkyl
  • each Rl is independently selected from the group consisting of:
  • each R2 is independently selected from the group consisting of:
  • n 0, 1 or 2;
  • n 0, 1 or 2;
  • R3 is H or C1-C3 alkyl
  • R4 is H or Cl-C3 alkyl
  • R5 is selected from the group consisting of:
  • Rb is C1-C6 alkyl
  • the compounds of Formula I has the structure of Formula 1(A)
  • Rl, R2, R3, R4, R5, m and n are defined as in Formula I.
  • the invention relates to the compounds of Formula I, wherein X is methylamino. In one embodiment, the invention relates to the compounds of Formula I, wherein X is methyl or ethyl.
  • this invention also relates to compounds of any of the above embodiments, wherein m is 0. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein m is 1.
  • this invention also relates to compounds of any of the above embodiments, wherein Rl is CI, In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein Rl is CN. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein Rl is CF 3 .
  • this invention also relates to compounds of any of the above embodiments, wherein n is 1, In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein n is 2. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein n is 0.
  • this invention also relates to compounds of any of the above embodiments, wherein R2 is CF3. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R2 is CI. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R2 is methoxy. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R2 is methyl.
  • this invention also relates to compounds of any of the above embodiments, wherein R3 is H. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R3 is CHj.
  • this invention also relates to compounds of any of the above embodiments, wherein R4 is H. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R4 is C3 ⁇ 4,
  • this invention also relates to compounds of any of the above embodiments, wherein R5 is C1-C3 alkyl. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R5 is ethyl.
  • R5 is C1-C3 alkyl. In one embodiment, this invention also relates to compounds of any of the above embodiments, wherein R5 is ethyl.
  • the meaning of any functional group or substituent thereon at any one occurrence in Formula I, or any subformula thereof, is independent of its meaning, or any other functional group's or substituent's meaning, at any other occurrence, unless stated otherwise.
  • the compounds according to Formula I may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof.
  • Chiral centers such as chiral carbon atoms, may also be present in a substituent such as an alkyl group.
  • the stereochemistry of a chiral center present in Formula I, or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
  • compounds according to Formula I containing one or more chiral center may be used as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
  • Individual stereoisomers of a compound according to Formula I which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzamatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral enviornment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • the compounds according to Formula I may also contain double bonds or other centers of geometric asymmetry. Where the stereochemistry of a center of geometric asymmetry present in Formula I, or in any chemical structure illustrated herein, is not specified, the structure is intended to encompass the trans (E) geometric isomer, the cis (Z) geometric isomer, and all mixtures thereof. Likewise, all tautomeric forms are also included in Formula I whether such tautomers exist in equilibrium or predominately in one form.
  • compounds according to Formula I may contain an acidic functional group. In certain other embodiments, compounds according to Formula I may contain a basic functional group.
  • pharmaceutically-acceptable salts of the compounds according to Formula I may be prepared. Indeed, in certain embodiments of the invention, pharmaceutically-acceptable salts of the compounds according to Formula I may be preferred over the respective free base or free acid because such salts may impart greater stability or solubility to the molecule thereby facilitating formulation into a dosage form. Accordingly, the invention is further directed to the use of pharmaceutically-acceptable salts of the compounds according to Formula I.
  • pharmaceutically-acceptable salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. These pharmaceutically-acceptable salts may be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.
  • the term "compounds of the invention” means both the compounds according to Formula I and the pharmaceutically-acceptable salts thereof.
  • a compound of the invention also appears herein and refers to both a compound according to Formula I and its pharmaceutically-acceptable salts.
  • the invention also includes various deuterated forms of the compounds of Formula (I). Each available hydrogen atom attached to a carbon atom may be independently replaced with a deuterium atom. A person of ordinary skill in the art will know how to synthesize deuterated forms of the compounds of Formula (I). Commercially available deuterated starting materials may be employed in the preparation of deuterated forms of the compounds of Formula (I), or they may be synthesized using conventional techniques employing deuterated reagents (e.g. lithium aluminum deuteride).
  • deuterated reagents e.g. lithium aluminum deuteride
  • the compounds of the invention may exist in solid or liquid form. In the solid state, the compounds of the invention may exist in crystalline or noncrystalline form, or as a mixture thereof.
  • pharmaceutically-acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice.
  • Hydrates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates.” Hydrates include stoichiometric hydrates as well as compositions containing vaiable amounts of water. The invention includes all such solvates.
  • polymorphs may exhibit polymorphism (i.e. the capacity to occur in different crystalline structures). These different crystalline forms are typically known as "polymorphs.”
  • the invention includes all such polymorphs. Polymorphs have the same chemical composition but differ in packing, geometrical arangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification.
  • polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, used in making the compound. For example, changes in temperature, pressure, or solvent may result in polymorphs. In addition, one polymorph may spontaneously convert to another polymorph under certain conditions.
  • the compounds according to Formula I are prepared using conventional organic syntheses. Suitable synthetic routes are depicted below in the following general reaction scheme. Starting materials and reagents depicted in the general reaction schemes below are commercially available or can be made from commercially available starting materials using methods known to those skilled in the art.
  • a substituent described herein is not compatible with the synthetic methods described herein, the substituent may be protected with a suitable protecting group that is stable to the reaction conditions.
  • the protecting group may be removed at a suitable point in the reaction sequence to provide a desired intermediate or target compound.
  • Suitable protecting groups and the methods for protecting and de-protecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which may be found in T. Greene and P. Wuts, Protecting Groups in Chemical Synthesis (3rd ed.), John Wiley & Sons, NY (1999).
  • a substituent may be specifically selected to be reactive under the reaction conditions used. Under these circumstances, the reaction conditions convert the selected substituent into another substituent that is either useful as an intermediate compound or is a desired substituent in a target compound.
  • Scheme 1 represents a general reaction scheme for preparing compounds of Formula I where X is O or NRa.
  • Starting material substituted aryl methyl ketones 1.1 can be transformed to thiazole amines 1.2 through a one pot iodination and cyclization cascade reaction. Bromination of 1.2 provides intermediates 1.3, which are attacked by substituted phenols or substituted phenyl anilines.
  • the obtained thiazole amines 1.4 can then be coupled with an appropriate acid (commercially available or can be made from commercially avail ble starting materials using methods known to those skilled in the art) to afford the desired compounds of Formula I.
  • Mobile phase water containing 0.05% TFA / acetonitrile.
  • Step 1 A solution of sodium nitrite (18.4 g) in 133 mL of water was added dropwise at 0 °C, while stirring, to a suspension of (4-aminophenyl)acetic acid (40.2 g) in 133 mL of water and 54 mL of concentrated hydrochloric acid. After the addition was complete, the reaction mixture was stirred at the same temperature for 45 minutes. This solution of cold diazonium salt was then added dropwise at room temperature to a mixture of potassium ethylxanthate (49.4 g), 80 mL of water and 200 mL of 2 M sodium carbonate solution. The mixture was heated to 45 °C and stirred at this temperature until gas evolution stops.
  • Step 2 (4- ⁇ [(Ethyloxy)carbonothioyl]thio ⁇ phenyl)acetic acid (90 g) was taken up in 340 mL of ethanol, and a solution of 70 g of potassium hydroxide in 340 mL of water was added. Boiling at reflux was effected for 20 hours. The major portion of ethanol was subsquently removed by the distillation under reduced pressure. The aqueous phase was cooled with ice, and acidified with concentrated hydrochloric acid while stirring. The obtained solution was extracted with diethyl ether (500 mL).
  • Step 3 To a solution of (4-mercaptophenyl)acetic acid (33 g) in N,N-dimethylformamide (DMF) (240 mL) was added 2 C0 3 (108 g) and bromoethane (64.1 g). The reaction mixture was stirred at RT. After 2.5 hours, the starting material was totally consumed. The reaction mixture was partitioned between ethyl acetate (300 mL) and water (300 mL).
  • DMF N,N-dimethylformamide
  • Step 4 A solution of ethyl [4-(ethylthio)phenyl] acetate (34 g) in dichloromethane (DCM) (500 mL) was cooled to 0 °C with an ice bath. MCPBA (78 g) was added in portions, and the reaction mixture was stirred at RT overnight. The obtained suspension was filtered. The filtrate was washed with sat. sodium carbonate solution (400 mL x 2), water (500 mL), then brine (250 mL), The obtained solution was dried over sodium sulphate, filtered, and concentrated.
  • DCM dichloromethane
  • Step 1 Iodine (3.33 g) was added to 1 ⁇ (4-chlorophenyl)ethanone (2.031 g) and thiourea (2 g). The reaction mixture was heated overnight at 100 °C. After cooling, the reaction mixture was triturated with diethyl ether (about 50 mL) to remove any unreacted iodine and l-(4- chlorophenyl)ethanone. The solid residue was put in cold distilled water (50 mL) and treated with ammonia solution to pH 9-10. 4-(4-Chlorophenyl)-l,3-thiazol-2-amine (2.6 g) was collected.
  • Step 2 To a mixture of 4-(4-chlorophenyl)-l,3-thiazol-2-amine (2.3 g) and copper(ll) bromide (3.94 g) was added acetonitrile (30 mL). The reaction mixture was stirred at room temperature overnight. Acetonitrile was removed under vacuum. EtOAc was added. The obtained mixture was washed with diluted ammonia 3 times.
  • Step 4 [4-(Ethylsulfonyl)phenyl]acetic acid (intermediate la, 31.8 mg), 4-(4-chlorophenyl)-5- [(4-methylphenyl)oxy]-l,3-thiazol-2-amine (44.1 mg), EDC (32.0 mg) and HOBt (25.6 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (4 mL) was added. The reaction mixture was stirred at RT for one and a half days. DCM was removed. The obtained crude was redissolved in THF and DMF, which was submitted to MDAP for purification under acidic conditions.
  • Step 2 [4-(Ethylsulfonyl)phenyl]acetic acid (intermediate la, 63.0 mg), 4-(4-chlorophenyl)-5- (phenyloxy)-l,3-thiazol-2-amine (83.5 mg), EDC (63.4 mg) and HOBt (50.7 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT for three days. DCM was removed. The obtained mixture was redissolved in DMF and purified by MDAP.
  • Step 1 To a mixture of thiourea (1.147 g) and 2-bromo-l-phenylethanone (3 g) was added ethanol (100 mL). The reaction mixture was heated up to reflux (oil bath temperature: 80 °C) for 2.5 hours. The reaction was cooled down to RT. Ethanol was removed under vacuum to afford the intermediate as a white solid. Copper(II) bromide (8.42 g) and acetonitrile (40 mL) were added. The mixture was stirred at RT for 3 days. Acetonitrile was removed under vacuum. EtOAc was added. The obtained mixture was washed with diluted ammonia three times until no blue color was observed in the aqueous phase.
  • Step 3 [4-(Ethylsulfonyl)phenyl]acetic acid (intermediate la, 150 mg), 4-phenyl-5- (phenyloxy)-l,3-thiazol-2-amine (176 mg), EDC (151 mg) and HOBt (121 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT for 3 days. DCM was removed. The obtained crude was redissolved in DMF and submitted to MDAP for purification.
  • Step 2 [4-(Ethylsulfonyl)phenyl] acetic acid (intermediate la, 152 mg), 5-[(2- chlorophenyl)oxy]-4-phenyl-l,3-thiazol-2-amine (202.2 mg), EDC (154 mg) and HOBt (123 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT for 3 days. DCM was removed. The obtained crude was redissolved in DMF and submitted to MDAP for purification.
  • Step 2 [4-(Ethylsulfonyl)phenyl] cetic acid (intermediate la, 118 mg), 4-phenyl-5- ⁇ [2- (trifluoromethyl)phenyl]oxy ⁇ -l,3-thiazol-2-amine (174.3 mg), EDC (119 mg) and HOBt (95 mg) were added into a 10 mL vial, Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT for 3 day. DCM was removed. The obtained crude was redissolved in DMF and submitted to MDAP for purification.
  • DCM Dichloromethane
  • Step 2 [4-(Ethylsulfonyl)phenyl]acetic acid (intermediate la, 139 mg), 5-[(4- chlorophenyl)oxy]-4-phenyl-l,3-thiazol-2-amine (184.6 mg), EDC (140 mg) and HOBt (112 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT for 3 days. DCM was removed. The obtained crude was redissolved in DMF and submitted to MDAP.
  • Step 2 [4-(Ethylsulfonyl)phenyl] acetic acid (intermediate la, 73.6 mg), 4-phenyl-5- ⁇ [4-
  • Step 2 [4-(Ethylsulfonyl)phenyl] acetic acid (intermediate la, 142 mg), 5- ⁇ [4-
  • Step 1 To a solution of l-(3-chlorophenyl)ethanone (15 g) in chloroform (100 mL) and ethyl acetate (100 mL) was added copper(II) bromide (21.67 g), and the reaction mixture was refluxed overnight. The reaction mixture was concentrated to give 2-bromo-l-(3-chlorophenyl)ethanone (18 g) as a brown oil. MS(ES + ) m/z 219 (MH ).
  • Step 2 To a solution of 2-bromo-l-(3-chlorophenyl)ethanone (28 g) in ethanol (300 mL) was added thiourea (10.04 g).
  • Step 3 To a solution of 4-(3-chlorophenyl)thiazol-2-amine (1 g) in tetrahydrofuran (20 mL) was added NBS (0.88 g). After stirring at room temperature overnight, the mixture was partitioned between ethyl acetate (30 mL) and water (20 mL). The organic phase was washed with water (20 mL x 2), dried and concentrated to give 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (1.05 g) as a red liquid. MS(ES ) m/z 289 (MH ).
  • Step 4 To a solution of 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (1.0 g) in acetone (50 mL) was added cesium carbonate (1.42 g) and 4-chlorophenol (0.5 g). The reaction mixture was stirred at 45 °C overnight. Solvent was removed, and ethyl acetate was added. The obtained solution was washed with water (40 mL x 3) and brine (30 mL x 2), dried and concentrated.
  • Step 1 To a solution of 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (1.0 g, see step 3 for synthesis of Example 9) in acetone (50 mL) was added cesium carbonate (1.4 g) and 2-chlorophenol (0.50 g). The reaction mixture was stirred at 45 °C overnight. Solvent was removed, and ethyl acetate was added. The obtained solution was washed with water (40 mL x 3) and brine (30 mL x 2), dried and concentrated.
  • Step 2 To a solution of 2-(4-(ethylsulfonyl)phenyl)acetic acid (intermediate la, 200 mg) in dichloromethane (DCM) (20mL) was added 5-(2-chlorophenoxy)-4-(3-chlorophenyl)thiazol-2-amine (300 mg), EDC (207 mg), HOBt (166 mg) and DIPEA (0.315 mL). After stirring at 35 °C for 2 days, the reaction mixture was washed with water (30 mL x 3), dried and concentrated.
  • DCM dichloromethane
  • Step 1 To a solution of 5-bromo-4-(3-chlorophenyl)thiazoI-2-amine (1.0 g, see step 3 for synthesis of Example 9) in acetone (10 mL) was added phenol (0.36 g) and cesium carbonate (1.35 g). The reaction mixture was stirred at 45 °C overnight. DCM (100 mL) was added. The obtained solution was washed with water (100 mL x 3), dried and concentrated. The residue was purified by flash chromatography (EtOAc : PE - 1:5 to 1: 1) to give 4-(3-chlorophenyl)-5-phenoxythiazol-2- amine (230 mg) as a red liquid. MS(ES " *) m/z 303 (MET 1 ⁇ .
  • Step 2 To a solution of 4-(3-chlorophenyl)-5-phenoxythiazol-2-amine (230 mg) in
  • DCM dichloromethane
  • Step 1 To a mixture of 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (2.0 g, see step 3 for synthesis of Example 9), 2-(trifluoromethyl)phenol (1.12 g) and cesium carbonate (2.70 g) was added acetone (10 mL). The reaction mixture was stirred at 45 °C overnight. After removal of solvent, the residue was partitioned between DCM (100 mL) and water (100 mL). The organic phase was washed with water (100 mL x 2), dried and concentrated.
  • Step 1 To a solution of 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (2.5 g, see step 3 for synthesis of Example 9) in acetone (50 mL) was added cesium carbonate (3.38 g) and 2,6- dichlorophenol (1.55 g). The reaction mixture was stirred at 45 °C for 2 days. DCM (50 mL) was added. The obtained solution was washed with water, dried and concentrated to give 4-(3- chlorophenyl)-5-(2,6-dichlorophenoxy)thiazol-2-amine (300 mg) as a red oil. MS(ES + ) m/z 370 (MH + ).
  • Step 1 To a solution of 3-acetylbenzonitrile (8 g) in chloroform (50 mL) and ethyl acetate (50 mL) was added copper(II) bromide (25.9 g). The reaction mixture was refluxed overnight. Solid was removed by filtration, and the filtrate was washed with sat. ammonium chloride and brine, dried, and concentrated to give 3-(2-bromoacetyl)benzonitrile (13 g) as a yellow oil. MS(ES ⁇ ) m/z 225 (MH ⁇ ).
  • Step 2 To a solution of 3-(2-bromoacetyl)benzonitrile (13 g) in ethanol (80 mL) was added thiourea (4.64 g). The reaction mixture was stirred for 5 mins. The white precipitate was collected by filtration to give 3-(2-aminothiazol-4-yl)benzonitrile (10 g). MSfES " ⁇ m/z 202 (MH 4 ).
  • Step 3 To a solution of 3-(2-aminothiazol-4-yl)benzonitrile (3 g) in tetrahydrofuran (THF) (60 mL) was added NBS (2.79 g). The reaction mixture was stirred at room temperature for 1 hour. EtOAc (80 mL) was added. The obtained solution was washed with water (50 mL x 3), dried and concentrated to give 5-bromo-4-(3-cyanophenyl)thiazol-2-amine (2.7 g) as a dark red solid. MSfES ⁇ ) m/z 279 (MH ).
  • Step 4 To a solution of 5-bromo-4-(3-cyanophenyl)thiazol-2-amine (1.0 g) in acetone (30 mL) was added cesium carbonate (1.5 g) and 4-(trifluoromethyl)phenol (0.6 g). The reaction mixture was stirred at 45 °C overnight. Solvent was removed, and ethyl acetate was added. The organic phase was washed by water (30 mL x 3) and brine (25 mL x 2), dried and concentrated.
  • Step 5 To a solution of 2-(4-(ethyIsulfonyl)phenyl)acetic acid (intermediate la, 220 mg) in dichloromethane (DCM) (20 mL) was added 3-(2-amino-5-(4-(trifluoromethyl)phenolxy)thiazol-4- yl)benzonitrile (310 mg), EDC (200 mg) ⁇ HOBt (150 mg) and DIPEA (0.30 mL). After stirring at 35 °C for 2 days, the mixture was washed with water (20 mL x 3), dried and concentrated.
  • DCM dichloromethane
  • Step 1 To a solution of l-(3-(trifluoromethyl)phenyl)ethanone (5 g) in chloroform (30 mL) and ethyl acetate (30 mL) was added copper(II) bromide (7.5 g). The reaction mixture was refluxed overnight. Solvent was removed to give 3-(trifluoromethyl)benzoyl bromide (6 g) as a brown oil. MS(ES + ) m/z 253 (MH ).
  • Step 2 To a solution of 3-(trifluoromethyl)benzoyl bromide (6 g) in ethanol (100 mL) was added thiourea (5.0 g). The reaction mixture was refluxed overnight. Solvent was removed. The residue was triturated with ethyl acetate to give 4-(3-(trifluoromethyl)phenyl)thiazol-2-amine (5 g) as a white solid. MS(ES ⁇ > m/z 245 (MH 4 ).
  • Step 3 To a solution of 4-(3-(trifluoromethyl)phenyl)thiazol-2-amine (5 g) in tetrahydrofuran
  • Step 4 To a solution of 5-bromo-4-(3-(trifluoromethyl)phenyl)thiazol-2-amine (1.0 g) in acetone (25 mL) was added cesium carbonate (1.4 g) and 2-hydroxybenzonitriIe (0.6 g). The reaction mixture was stirred at 45 °C overnight. Solvent was removed, and ethyl acetate was added. The organic phase was washed with water (30 mL x 3) and brine (20 mL x 2), dried and concentrate.
  • Step 2 To a solution of 3-(2-amino-5-(2-chloro-4-(trifluoromethyl)phenoxy)thiazol-4- yl)benzonitrile (300 mg) and 2-(4-(ethylsulfonyl)phenyl)acetic acid (intermediate la, 208 mg) in DCM (50 mL) was added EDC (436 mg), HOBt (139 mg) and DIPEA (0.79 mL). After stirring at reflux overnight, the mixture was washed with water (40 mL x 3), dried and concentrated.
  • Step 1 Lithium chloride (2.30 g) was added to a solution of l-methoxy-4-nitro-2- (trifluoromethyl)benzene (4 g) in NN-dimethylformamide (40 mL) at room temperature. The reaction mixture was stirred at 160 °C for 5 hours. After cooling to RT, the solution was diluted with EtOAc (300 mL). The mixture was washed with water (100 mL x 2) and brine (100 mL), dried and concentrated to give 4-nitro-2-(trifluoromethyl)phenol (3.5 g) as a yellow solid.
  • Step 2 Zinc (4.42 g) was added to a solution of 4-nitro-2-(trifluoromethyl)phenol (3.5 g) and ammonium formate (8.52 g) in methanol (5 mL) and water (5 mL) at room temperature. The reaction mixture was stirred at 80 °C for 3 hours. After cooling to room temperature, the mixture was filtered and EtOAc (80 mL) was added to the filtrate. The organic layer was washed with water (30 mL) and brine (40 mL), dried, and concentrated to afford 4-amino-2-(trifluoromethyl)phenol (2.8 g) as a yellow solid.
  • Step 3 Sodium nitrite (0.47 g) in 3 ⁇ 40 (3 mL) was added dropwise to a solution of 4-amino-2- (trifluoromethyl)phenol (1 g) in acetonitrile (20 mL) and hydrochloric acid (10 mL) at 0 °C . After stirring for 0.5 hour, copper(I) chloride (1.12 g) in 3 M HC1 (5 mL) was added to the mixture. Then the reaction mixture was stirred at 100 °C for 6 hours. After cooling to room temperature, the solution was diluted with EtOAc (200 mL). The organic phase was washed with water (100 mL) and brine (50 mL), dried, and concentrated.
  • Step 4 5-Bromo-4-(3-cyanophenyl)thiazol-2-amine 3-(2-Amino-5-bromothiazol-4- yl)benzonitrile (500 mg, see step 3 for synthesis of Example 15) was added to a solution of 4-chloro- 2-(trifluorometliyl)phenol (351 mg) and Cs 2 C0 3 (872 mg) in acetone (30 mL) at room temperature. The reaction mixture was stirred at 45 °C for 4 hours. The reaction mixutre was cooled to room temperature, filtered through celite and concentrated.
  • Step 5 3-(2-Amino-5-(4-chloro-2-(trifluoromethyl)phenoxy)thiazoI-4-yl)benzonitrile (170 mg) was added to a solution of 2-(4-(ethylsulfonyl)phenyl)acetic acid (intermediate la, 147 mg), HOBt (79 mg,), EDC (247 mg) and DIPEA (0.45 mL) in dichloromethane (15 mL) at room temperature. The reaction mixture was stirred at 40 °C for 12 hours. The mixture was cooled to room temperature and concentrated.
  • Step 1 Bromine (4.59 mL) was added into a solution of l,3-diphenyl-l,3-propanedione (20 g) in ethyl acetate (50 mL) dropwise at 0 °C. After the addition was complete, the resultant mixture was stirred at 0 °C until the color of bromine faded away. Solvent was removed in vacuo. The residue and thiourea (6.79 g) was dissolved into N ; N-dimethylformamide (DMF) (20 mL) and the solution was heated to 85 °C for 15 mins. The mixture was cooled down, poured into water, basified by NaHC0 3 , and extracted with EtOAc (3 times).
  • DMF N-dimethylformamide
  • Step 2 A mixture of [4-(ethylsulfonyl)phenyI]acetic acid (intermediate la, 598 mg), EDC (718 mg) and HOBt (506 mg) in dichloromethane (DCM) (10 mL) was stirred at room temperature under nitrogen for 10 mins. (2-Amino-4-phenyl-l,3-thiazol-5-yl)(phenyl)methanone (700 mg) was then added. After stirring at room temperature overnight, the reaction mixture was partitioned between DCM and water. The aqueous phase was extracted with DCM for 3 times.
  • DCM dichloromethane
  • Step 3 NaBH 4 (11 mg) was added into a solution of 2-[4-(ethylsulfonyl)phenyl]-N-[4-phenyl- 5-(phenylcarbonyl)-l,3-thiazol-2-yl]acetamide (100 mg) in methanol (2 mL) at room temperature in 3 portions. The reaction mixture was stirred at the same temperature for 1.5 hours. The mixture was poured into sat. NH 4 CI solution, and then extracted with EtOAc for 3 times. The combined organic layers were washed with brine and dried over anhydrous Na 2 S0 .
  • Step 1 A mixture of 3-phenylpropanoic acid (5 g), N,C-dimethylhydroxylamine (3.9 g), HOBt (6.1 g), EDC (7.7 g) and Et 3 N (9.3 mL) in dichloromethane (DCM) (80 mL) was stirred at 25 °C overnight. The mixture was washed with 1 M HC1, sat. NaHC(1 ⁇ 4 and brine successively. The organic phase was dried over anhydrous Na 2 S0 4 .
  • DCM dichloromethane
  • Step 2 To a solution of N-methoxy-N-methyl-3-phenylpropanamide (4.5 g) in tetrahydrofuran (THF) (60 mL) stirred at 0 °C was added a solution of phenylmagnesium bromide (34 mL) (1 M in THF) dropwise. After stirring at 0 °C for 3 hours, the reaction mixture was quenched with sat. NH 4 C1 solution, and then extracted with EtOAc (80 mL). The organic phase was washed with brine, dried over anhydrous Na 2 SO,j, and concentrated in vacuo to afford 1,3-diphenylpropan-l-one (2.2 g) as a yellow solid. MS(ES + ) m/z 211 (MH ).
  • Step 3 A mixture of 1,3-diphenylpropan-l-one (2.2 g) and copper(II) bromide (3.8 g) in chloroform (20 mL) and ethyl acetate (20 mL) was stirred at reflux for 2 hours. Solvent was removed, and the residue was partitioned between water (20 mL) and EtOAc (50 mL). The organic phase was dried and concentrated to give 2-bromo- 1,3-diphenylpropan-l-one (2.6 g) as a yellow solid. MS(ES + ) m/z 289 (MH").
  • Step 4 A mixture of 2-bromo- 1,3-diphenylpropan-l-one (3.5 g) and thiourea (1.1 g) in ethanol (30 mL) was heated at reflux for 2 hours. Solvent was removed in vacuo. The residue was washed with EtOAc and water, filtered and dried to afford 4-phenyl-5-(phenylmethyl)-l,3-thiazol-2-amine (1.7 g) as a yellow soild. MS(ES + ) m/z 267 (MH").
  • [4-(Ethylsulfonyl)pbenyl]acetic acid (intermediate la, 89 mg), 4-phenyl-5-(phenylmethyl)-l,3- thiazol-2-amine (intermediate 21a, 104 mg), EDC (90 mg) and HOBt (71.7 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT over 3 days. DCM was removed. The obtained crude was redissolved in DMF and submitted to MDAP for purification.
  • Step 1 To a solution of 1,3-diphenylbutan-l-one (300 mg) in chloroform (10 mL) and ethyl acetate (10 mL) was added copper(II) bromide (657 mg). The reaction mixture was stirred at 85 °C for 3 hours. Solvent was removed, and the residue was partitioned between ethyl acetate (50 mL) and water (30 mL). The aqueous phase was extracted with ethyl acetate (30 mL x 2). The combined organic phases were dried and concentrated to give 2-bromo-l,3-diphenyibutan-l-one (400 mg) as a yellow solid. MS(ES ⁇ mfz 303 (MfT).
  • Step 3 A mixture of 4-phenyl-5-(l-phenylethyl)thiazol-2-amine (70 mg), 2-(4- (ethylsulfonyl)phenyl)acetic acid (intermediate la, 68.4 mg), HOBt (42.1 mg) and EDC (52.6 mg) in dichloromethane (DCM) (15 mL) was stirred at RT overnight The mixture was washed with water (60 mL x 3) and brine (60 mL). The organic phase was dried over anhydrous Na 2 S0 4 , and concentrated.
  • DCM dichloromethane
  • Step 1 Borane-tetrahydrofuran complex (17.67 mL) was added dropwise to a solution of 3-(2- chlorophenyl)propanoic acid (1.3 g) in THF (50 mL) cooled at 0 °C over 30 mins. The reaction mixture was warmed to room temperature and stirred overnight, The mixture was then cooled to 0 °C and quenched with brine. The organic layer was separated, and the aqueous layer was extracted with etiryl acetate (100 mL x 2). The combined organic phases were dried over sodium sulfate and concentrated to afford 3-(2-chlorophenyl)propan-l-ol (1.7 g) as a yellow oil. MSfES ⁇ m/z 153 ((MH- H 2 0) + ).
  • DCM dichloromethane
  • DCM dichloromethane
  • Step 5 A mixture of 3-(2-chlorophenyl)-l -(3-chlorophenyl)propan-l-one (0.68 g) and copper(II) bromide (1.09 g) in chloroform (10 mL) and ethyl acetate (10 mL) was stirred at 85 °C for 3 hours. Solvent was removed, and the residue was partitioned between water (30mL) and ethyl acetate (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL x 2).
  • Step 6 A mixture of 2-bromo-3-(2-chlorophenyl)-l-(3-chlorophenyl)propan-l-one (800 mg) and thiourea (340 mg) in ethanol (20 mL) was stirred at 85 °C overnight. Solvent was removed. The residue was suspended in CH 2 C1 2 (30 mL), and the mixture was filtered to remove insoluble solid.
  • Step 1 To a mixture of thiourea (3.42 g) and 2-bromo-l-(4-chlorophenyl)ethanone (10.5 g) was added ethanol (100 mL). The reaction mixture was heated up to reflux (oil bath temperature: 85 °C) overnight. The reaction mixture was cooled to RT. Solid was filtered off and washed with diethyl ether to afford 4-(4-chlorophenyl)-l,3-thiazol-2-amine as a white solid. MSfES ) m/z 211 (Nfflf).
  • Step 2 To a mixture of 4-(4-chIorophenyl)-l,3-thiazol-2-amine (3.8 g) and copper(II) bromide (12.48 g) was added acetonitrile (30 mL). The reaction mixture was stirred at room temperature overnight. Acetonitrile was removed in vacuo. EtOAc was added. The obtained mixture was washed with diluted ammonia 3 times. The organic phase was then washed with brine and dried over Na2SC>4.
  • Step 3 To a solution of N-methylaniline (49.6 mg, 0.463 mmol) in NN-dimethylformamide (DMF) (0.5 mL) was added sodium hydride (23.13 mg). The vial was sealed and stirred at RT for 40 mins. A solution of 5-bromo-4-(4-chIorophenyl)-l ,3-thiazol-2-amine (67 mg) in NN- dimethylformamide (DMF) (0.5 mL) was carefully added at 0 °C. The reaction mixture was stirred at this temperature for 10 mins, and then quenched with water. The obtained mixture was extracted with EtOAc for 3 times. The combined organics were washed with brine, dried over Na 2 SC> .
  • Step 4 [4-(Ethylsulfonyl)phenyl]acetic acid (intermediate la, 44 mg), 4-(4-chlorophenyl)-N 5 - methyl-A ⁇ -phenylthiazole ⁇ -diamine (60.9 mg), EDC (44.3 mg) and HOBt (35.4 mg) were added into a 10 mL vial.
  • Dichloromethane (DCM) (5 mL) was added. The reaction mixture was stirred at RT for 3 days. DCM was removed. The obtained crude was redissolved in DMF and submitted to MDAP for purification. Solvent was evaporated in vacuo to give N- ⁇ 4-(4-chlorophenyl)-5-
  • Step 1 A mixture of 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (2 g, see step 3 for synthesis of Example 9), 2-chloro-N-methylbenzenamine (1.08 g) and cesium carbonate (2.70 g) in acetone (5 mL) was stirred at 55 °C overnight. Solvent was removed, and the residue was partitioned between DCM (10 mL) and water (10 mL). The organic phase was washed with water (10 mL x 3), dried and concentrated to give A ⁇ -(2-chlorophenyl)-4-(3-chlorophenyl)-N 5 -methylthiazole-2,5-diamine (400 mg) as a red solid. MStES*) m z 351 (MET 1 ).
  • Step 2 A mixture of 2-(4-(ethylsuIfonyI)phenyl)acetic acid (intermediate 1 a, 313 mg), ⁇ -(2- chloropheny ⁇ S-chlorophenyli-A ⁇ -methyltliiazole ⁇ .S-diamine (400 mg), EDC (657 mg), HOBt (210 mg) and DIPEA (1.20 mL) in dichloromethane (DCM) (20 mL) was stirred at 45 °C overnight. DCM (50 mL) and water (50 mL) were added. The organic phase was washed with water (30 mL x 3), dried and concentrated.
  • DCM dichloromethane
  • Step 1 To a solution of 5-bromo-4-(3-chlorophenyl)thiazoI-2-amine (1.0 g, see step 3 for synthesis of Example 9) in acetone (50 mL) was added cesium carbonate (1.4 g) and 2- isopropylphenol (0.51 g). The reaction mixture was stirred at 45 °C overnight. After removal of solvent, ethyl acetate was added. The organic solution was washed with water (30 mL x 3) and brine (25 mL x 2), dried and concentrated.
  • Step 2 To a solution of 2-(4-(ethylsulfonyl)phenyl)acetic acid (intermediate l , 200 mg) in dichloromethane (DCM) (25 mL) was added 4-(3-chlorophenyl)-5-(2-isopropylphenoxy)thiazol-2- amine (300 mg), EDC (207 mg), HOBt (166 mg) and DIPEA (0.315 mL). After stirring at 35 °C for 2 days, the mixture was washed with water (40 mL x 3), dried and concentrated.
  • DCM dichloromethane
  • Step 1 To a solution of 5-bromo-4-(3-chlorophenyl)thiazol-2-amine (1.0 g, see step 3 for synthesis of Example 9) in acetone (50 mL) was added cesium carbonate (1.4 g) and 4- methoxyphenol (0.48 g). The reaction mixture was stirred at 45 °C overnight. Solvent was removed, and ethyl acetate was added. The obtained solution was washed with water (40 mL x 3) and brine (30 mL x 2), dried and concentrated.
  • Step 2 To a solution of 2-(4-(ethyIsulfonyl)phenyl)acetic acid (intermediate la, 200 mg) in dichloromethane (DCM) (20 mL) was added 4-(3-chlorophenyl)-5-(4-methoxyphenoxy)thiazol-2- amine (280 mg), EDC (207 mg), HOBt (166 mg) and DIPEA (0.315 mL). After stirring at 35 °C for 2 days, the reaction mixture was washed with water (25 mL x 3), dried and concentrated.
  • DCM dichloromethane
  • Step 2 A mixture of l-(3-(bromomethyl)phenyl)ethanone (2.4 g), dimethylamine
  • Step 3 Bromine (568 mg) in acetic acid (30 mL) was added dropwise to a solution of l-(3- ((dimethylamino)methyl)phenyl)ethanone (700 mg) in acetic acid (20 mL) at 10 °C. The reaction mixture was stirred overnight. Solvent was removed to give 2-bromo-l -(3- ((dimethylamino)methyl)phenyl)ethanone (1.0 g) as an oil. MSfES ) m/z 256 (MET).
  • Step 4 A mixture of 2-bromo-l -(3-((dimethylamino)methyl)phenyl)ethanone (1.0 g) and thiourea (0.535 g) in ethanol (10 mL) was stirred at 80 °C overnight. Solvent was removed to give 4- (3-((dimethylamino)methyl)phenyl)thiazol-2-amine (800 mg). MS(ES + ) m/z 234 (MH ⁇ ).
  • Step 5 NBS (336 mg) was added to a solution of 4-(3-((dimethylamino)methyl)phenyl)thiazoI- 2-amine (800 mg) in THF (10 mL). The reaction mixture was stirred at room temperature for 30 mins. Solvent was removed to give 5-bromo-4-(3-((dimethylamino)methyl)phenyl)thiazol-2-amine (800 mg). MSCES ) m z 312 (MH ⁇ .
  • Step 6 To a solution of 5-bromo-4-(3-((dimethylamino)methyl)phenyl)thiazol-2-amine (800 mg) in acetone (50 mL) was added 2-(trifluoromethyl)phenol (571 mg) and cesium carbonate (1.25 g). The reaction mixture was stirred at 45 °C overnight. Solvent was removed, and ethyl acetate was added. The organic phase was washed with water (50 mL x 3), dried and concentrated.
  • Step 7 To a solution of 4-(3-((dimethylamino)methyl)phenyl)-5-(2- (trifluoromethyl)phenoxy)thiazol-2-amine (100 mg) in DCM (15 mL) was added 2-(4- (ethylsulfonyl)phenyl)acetic acid (intermediate la, 87 mg), HOBt (46.7 mg), EDC (146 mg) and DIPEA (0.266 mL). After stirring at reflux overnight, the mixture was washed with water and brine, dried and concentrated.
  • the compounds according to Formula I are RORy modulators, and are useful in the treatment of diseases mediated by RORy.
  • the biological activities of the compounds according to Formula I can be determined using any suitable assay for determining the activity of a candidate compound as a RORy modulator, as well as tissue and in vivo models.
  • This assay is based on the knowledge that nuclear receptors interact with cofactors (transcription factors) in a ligand dependent manner.
  • RORy is a typical nuclear receptor in that it has an AF2 domain in the ligand binding domain (LBD) which interacts with co-activators.
  • LBD ligand binding domain
  • the sites of interaction have been mapped to the LXXLL motifs in the co-activator SRC 1(2) sequences. Short peptide sequences containing the LXXLL motif mimic the behavior of full-length co-activator.
  • the assay measures ligand-mediated interaction of the co-activator peptide with the purified bacterial-expressed RORy ligand binding domain (RORy-LBD) to indirectly assess ligand binding.
  • RORy has a basal level of interaction with the co-activator SRC 1(2) in the absence of ligand, thus it is possible to find ligands that inhibit or enhance the RORy/SRCl(2) interaction.
  • RORy-LBD Human RORy Ligand Binding Domain
  • BL21(DE3) as an amino-terminal polyhistidine tagged fusion protein.
  • DNA encoding this recombinant protein was sub-cloned into a modified pET21a expression vector (Novagen).
  • a modified polyhistidine tag (M HHHHHHLVPRGS) was fused in frame to residues 263-518 of the human RORy sequence.
  • E.coli cell pellet was resuspended in 300 ml of lysis buffer (30 mM imidazole pH 7.0 and 150 mM NaCl), Cells were lysed by sonication and cell debris was removed by centrifugation for 30 minutes at 20,000g at 4°C. The cleared supernatant was filtered through a 0.45 uM cellulose acetate membrane filter. The clarified lysate was loaded onto a column (XK-26) packed with ProBond Nickel Chelating resin (InVitrogen), pre-equilibrated with 30 mM imidazole pH 7.0 and 150 mM NaCl.
  • lysis buffer 30 mM imidazole pH 7.0 and 150 mM NaCl
  • the column was developed with a gradient from 30 to 500 mM imidazole pH 7.0. Column fractions containing the RORy-LBD protein were pooled and concentrated to a volume of 5 mis. The concentrated protein was loaded onto a Superdex 200 column pre-equilibrated with 20 mM Tris-Cl pH 7.2 and 200 mM NaCl. The fractions containing the desired RORy-LBD protein were pooled together.
  • Purified RORy-LBD was buffer exchanged by exhaustive dialysis [3 changes of at least 20 volumes (>8000x)] against PBS [lOOmM NaPhosphate, pH 8 and 150mM NaCl].
  • concentration of RORy-LBD was approximately 30uM in PBS.
  • Five-fold molar excess of NHS-LC-Biotin (Pierce) was added in a minimal volume of PBS. This solution was incubated with occasional gentle mixing for 60 minutes at ambient room temperature.
  • the modified RORy-LBD was dialyzed against 2 buffer changes - TBS pH 8.0 containing 5mM DTT, 2mM EDTA and 2% sucrose - each at least 20 times of the volume.
  • the modified protein was distributed into aliquots, frozen on dry ice and stored at -80°C.
  • the biotinylated RORy-LBD was subjected to mass spectrometric analysis to reveal the extent of modification by the biotinylation reagent. In general, approximately 95% of the protein had at least a single site of biotinylation and the overall extent of biotinylation followed a normal distribution of multiple sites ranged from one to five.
  • biotinylated SRC 1(2) solution was prepared by adding an appropriate amount of biotinylated SRC 1(2) from the lOOuM stock solution to a buffer containing 10 mM of freshly added DTT from solid to give a final concentration of 40 nM.
  • An appropriate amount of Europium labeled Streptavidin was then added to the biotinylated SRC 1(2) solution in a tube to give a final concentration of 10 nM. The tube was inverted gently and incubated for 15 minutes at room temperature. Twenty-fold excess biotin from the 10 mM stock solution was added and the tube was inverted gently and incubated for 10 minutes at room temperature.
  • biotinylated RORy-LBD solution was prepared by adding an appropriate amount of biotinylated RORy-LBD from the stock solution to a buffer containing 10 mM of freshly added DTT from solid to give a final concentration of 40 nM.
  • An appropriate amount of APC labeled Streptavidin was then added to the biotinylated RORy-LBD solution in a tube to give a final concentration of 20 nM. The tube was inverted gently and incubated for 15 minutes at room temperature. Twenty-fold excess biotin from the 10 mM stock solution was then added and the tube was inverted gently and incubated for 10 minutes at room temperature.
  • Equal volumes of the above-described Europium labeled SRC 1(2) peptide and the APC labeled RORy-LBD were gently mixed together to give 20nM RORy-LBD, ⁇ APC-Strepavidin, 20nM SRC1(2) and 5nM Europium-Streptavidin.
  • the reaction mixtures were incubated for 5 minutes.
  • 25 ul of the reaction mixtures per well was added to the 384-well assay plates containing lul of test compound per well in 100% DMSO. The plates were incubated for lhour and then read on ViewLux in Lance mode for EU/APC.
  • RORy is known to bind to a CNS (conserved non-coding sequences) enhancer element in the IL17 promoter.
  • RORy activity is indirectly assessed using a luciferase reporter construct which contains the human IL17 promoter having the RORy-specific CNS enhancer element.
  • the 3 Kb human IL17 promoter containing the RORy- specific CNS enhancer element was PCR amplified from human genomic DNA and cloned into a pGL4-Luc2/hygro reporter plasmid sequencially as Xhol-Hindlll (1.1 Kb) and Kpnl-Xhol (1.9 Kb) fragments.
  • PCR was used to amplify human IL17 proximal promoter region from genomic DNA of 293T cells using primers as follows: forward primer, 5'- CTCGAGT AGAGCAGG AC AGGGAGGAA-3 1 (Xhol site is underlined) and reverse primer, 5'- AAGCTTGGATGGATGAGTTTGTGCCT-3 1 (Hindlll site is underlined).
  • forward primer 5'- CTCGAGT AGAGCAGG AC AGGGAGGAA-3 1 (Xhol site is underlined)
  • reverse primer 5'- AAGCTTGGATGGATGAGTTTGTGCCT-3 1 (Hindlll site is underlined).
  • the 1.1 kb DNA bands were excised, purified, and inserted into pMD19-T Simple Vector (Takara).
  • the 1.1 kb DNA was digested with Xhol and Hindlll and inserted into Xhol/Hindlll sites of pGL4.31[luc2P/GAL4UAS Hygro] (Promega) to generate the pIL17-lkb-hic reporter construct.
  • PCR was used to amplify human IL17 promoter region from genomic DNA using primers as follows: forward primer,5'-
  • the luciferase reporter plasmid and the RORyt overexpression plasmid were transfected into Jurkat cell line and a stable clone was identified.
  • the stable clone was grown in 10% dialyzed FBS in RPMI (1640) with 800ug/ml geneticin and 400ug/ml hygromecin.
  • Mouse CD4+ cells were purified using the CD4+ T Cell Isolation II Kit according to manufacturer's instructions (Miltenyi Biotec). 96 well plates were pre-coated with anti-CD3 antibody. Un-coated wells were used as controls. CD4+ Cells were resuspended in RPMI complete medium and were added to the 96-well plates at 3E5 cells/well, with the total volume being 90 ul. Cytokine cocktail and 20ul of each compound were then added to the wells (DMSO final volume 0.1%).
  • the final concentrations of antibodies (R&D Systems) and cytokines (R&D Systems) were: anti-mCD3, 5ug ml; anti-mCD28, 2ug/ml; anti-mlFNy, lOug ml; Anti-mIL4, lOug/ml; mIL-6, 20ng ml; mIL-23, lOng ml; mIL- ⁇ , lOng/ml; TGF- ⁇ , lOng/ml.
  • the culture was incubated in 37°C for 3 days and supematants were collected for ELISA.
  • the IL-17 ELISAs were performed according to manufacturer's instructions (R&D Systems).
  • Thl7 differentiation culture described above was maintained for 5 days and cells were analyzed by IL-17 and IFN- ⁇ intracellular staining according to manufacturer's instructions (BD Biosciences).
  • the data described below represents a mean pIC50 value of multiple test results if the test was performed more than once. It is understood that the data illustrated below may have reasonable variation depending on the specific conditions and procedures used by the person conducting the testing.
  • EAE Experimental Autoimmune Encephalomyelitis
  • Collagen-induced arthritis is an animal model of rheumatoid arthritis.
  • CIA can be induced in 8-week old male DBA/1 mice via an initial intradermal (i.d.) injection of an emulsion consisting of bovine type II collagen in CFA.
  • Mice are intraperitoneally (i.p.) injected with bovine type II collagen 21 days later to boost the immune system, resulting in chronic inflammation in both the hind and the front paws. Each compound is given to the mice at lOOmg/kg twice a day starting from day 20 after the first immunization. Mice are examined for onset and severity of disease in a blinded manner.
  • Arthritis symptoms can be graded by the following scoring system: grade 0, normal appearance; grade 1, slight erythema/ edema (1-3 digits); grade 2, erythema/ edema in more than 3 digits or mild swelling in ankle/wrist joint; grade 3, erythema edema in entire paw; grade 4, massive erythema/ edema of entire paw extending into proximal joints, ankylosis, loss of function. Each limb is graded, giving a maximum possible score of 16 per mouse. Clinical score data can be expressed as means ⁇ s.e.m. Foot volume of the mice can be determined using a YLS-7B foot volume measuring instrument (Shandong Academy of Medical Science).
  • the compounds of the invention are modulators of RORy and can be useful in the treatment of diseases mediated by RORy, particularly autoimmune or inflammatory diseases.
  • the Inflammatory or autoimmune diseases of the invention include multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, Sjorgen's syndrome, optic neuritis, chronic obstructive pulmonary disease, asthma, type I diabetes, neuromyelitis optica, Myasthenia Gavis, uveitis, Guillain- Barre syndrome, psoriatic arthritis, Gaves' disease and allergy. Accordingly, in another aspect the invention is directed to methods of treating such diseases.
  • the methods of treatment of the invention comprise administering a safe and effective amount of a compound according to Formula I or a pharmaceutically-acceptable salt thereof to a patient in need thereof.
  • "treat" in reference to a condition means: (1) to ameliorate or prevent the condition or one or more of the biological manifestations of the condition, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the condition or (b) one or more of the biological manifestations of the condition, (3) to alleviate one or more of the symptoms or effects associated with the condition, or (4) to slow the progression of the condition or one or more of the biological manifestations of the condition.
  • prevention of a condition includes prevention of the condition.
  • prevention is not an absolute term. In medicine, “prevention” is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a condition or biological manifestation thereof, or to delay the onset of such condition or biological manifestation thereof.
  • safe and effective amount in reference to a compound of the invention or other pharmaceutically-active agent means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects (at a reasonable benefit/risk ratio) within the scope of sound medical judgment.
  • a safe and effective amount of a compound will vary with the particular compound chosen (e.g. consider the potency, efficacy, and half -life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the patient being treated; the medical history of the patient to be treated; the duration of the treatment; the nature of concurrent therapy; the desired therapeutic effect; and like factors, but can nevertheless be routinely determined by the skilled artisan.
  • patient refers to a human or other animal.
  • the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
  • Parenteral administration refers to routes of administration other than enteral, transdermal, or by inhalation, and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • Topical administration includes application to the skin as well as intraocular, otic, intravaginal, and intranasal administration.
  • the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can he determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • Typical daily dosages may vary depending upon the particular route of administration chosen. Typical daily dosages for oral administration range from 0.1 mg to 1000 mg.
  • a prodrug of a compound of the invention is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of the invention in vivo.
  • Administration of a compound of the invention as a prodrug may enable the skilled artis n to do one or more of the following: (a) modify the onset of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome or overcome a side effect or other difficulty encountered with the compound.
  • Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymatically cleaved in vivo. Such modifications, which include the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
  • the invention relates to the use of the compounds of the invention in the preparation of a medicament for the treatment of diseases mediated by RORy.
  • the invention relates to the compounds of the invention for use in the treatment of diseases mediated by RORy.
  • diseases include autoimmune or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, Sjorgen's syndrome, optic neuritis, chronic obstructive pulmonary disease, asthma, type I diabetes,
  • compositions The compounds of the invention will normally, but not necessarily, be formulated into pharmaceutical compositions prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and one or more pharmaceutically-acceptable excipient.
  • compositions of the invention may be prepared and packaged in bulk form wherein a safe and effective amount of a compound of the invention can be extracted and then given to the patient such as with powders or syrups.
  • pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form wherein each physically discrete unit contains a safe and effective amount of a compound of the invention.
  • the pharmaceutical compositions of the invention typically contain from 0.1 mg to 1000 nig-
  • compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. For example, in certain embodiments the pharmaceutical compositions of the invention contain two compounds of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
  • pharmaceutically-acceptable excipient means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
  • each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
  • dosage forms include those adapted for (1) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as dry powders, aerosols, suspensions, and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets
  • parenteral administration such as sterile solutions, suspensions, and powders for reconstitution
  • transdermal administration such as transdermal patches
  • rectal administration such as
  • Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically-acceptable excipients include the following types of excipients: Diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients include the following types of excipients: Diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents
  • Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically- acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a safe and effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder.
  • Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch), gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose).
  • the oral solid dosage form may further comprise a disintegrant.
  • Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant Suitable lubricants include stearic acid, magnesuim stearate, calcium stearate, and talc.

Abstract

L'invention concerne des modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma (RORγ) de formule I et leur utilisation pour le traitement de maladies médiées par RORγ, les radicaux ayant les significations telles que définies dans l'invention.
PCT/CN2012/070678 2011-01-24 2012-01-20 Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma WO2012100734A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011070523 2011-01-24
CNPCT/CN2011/070523 2011-01-24

Publications (1)

Publication Number Publication Date
WO2012100734A1 true WO2012100734A1 (fr) 2012-08-02

Family

ID=46580229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/070678 WO2012100734A1 (fr) 2011-01-24 2012-01-20 Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma

Country Status (1)

Country Link
WO (1) WO2012100734A1 (fr)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019626A1 (fr) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et procédés
WO2013029338A1 (fr) * 2011-09-01 2013-03-07 Glaxo Group Limited Nouveaux composés
WO2013064231A1 (fr) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
WO2013079223A1 (fr) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolocarboxamides en tant que modulateurs de l'activité d'un récepteur orphelin gamma (rorϒ, nr1f3) apparenté au récepteur nucléaire orphelin rar et destinés au traitement de maladies inflammatoires chroniques et auto-immunes
WO2013171729A2 (fr) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt
WO2013178362A1 (fr) 2012-05-31 2013-12-05 Phenex Pharmaceuticals Ag Thiazoles substitués par carboxamide ou sulfonamide et dérivés apparentés en tant que modulateurs du récepteur nucléaire orphelin ror[gamma]
WO2014023367A1 (fr) 2012-08-09 2014-02-13 Phenex Pharmaceuticals Ag Hétérocycles à 5 chaînons contenant de l'azote substitués par carboxamide ou sulfonamide en tant que modulateurs pour le récepteur nucléaire orphelin ror gamma
WO2014062938A1 (fr) * 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Modulateurs du récepteur gamma orphelin associé aux rétinoïdes (rory)
WO2014179564A1 (fr) * 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Inhibiteurs du ror-gamma à base de thiazalopyrrolidine
WO2015052675A1 (fr) * 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Utilisation de composés substitués dihydro-benzimidazole comme modulateurs du ror gamma
WO2015087234A1 (fr) 2013-12-10 2015-06-18 Glenmark Pharmaceuticals S.A. Analogues de l'indole héteroaryle bicyclique utiles en tant que modulateurs de gamma ror
CN104926733A (zh) * 2014-03-18 2015-09-23 北京韩美药品有限公司 作为RORγ调节剂的化合物
WO2015159233A1 (fr) 2014-04-16 2015-10-22 Glenmark Pharmaceuticals S.A. Composés éther d'aryle et éther d'hétéroaryle en tant que modulateurs de ror gamma
WO2015198232A1 (fr) 2014-06-25 2015-12-30 Piramal Enterprises Limited Composés de triterpène fusionnés et utilisations de ceux-ci
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016145298A1 (fr) 2015-03-12 2016-09-15 The Regents Of The University Of California Méthodes de traitement du cancer par des inhibiteurs de ror gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3101008A1 (fr) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
WO2016193894A1 (fr) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Traitement de troubles respiratoires au moyen d'inhibiteurs ror-gamma
WO2017021879A1 (fr) 2015-08-03 2017-02-09 Glenmark Pharmaceuticals S.A. Nouveaux composés utilisés en tant que modulateurs de ror gamma
EP2975031A4 (fr) * 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9868724B2 (en) 2014-05-28 2018-01-16 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018011746A1 (fr) 2016-07-14 2018-01-18 Cadila Healthcare Limited Dérivés de cyclopropyle en tant que modulateurs de ror-gamma
WO2018011747A1 (fr) 2016-07-14 2018-01-18 Cadila Healthcare Limited Composés polycycliques en tant que modulateurs de ror-gamma
US9902735B2 (en) 2014-05-28 2018-02-27 Glaxosmithkline Intellectual Property Development Limited Heteroaryl substituted compounds as RORγ inhibitors
US9902715B2 (en) 2014-05-28 2018-02-27 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018042342A1 (fr) 2016-08-30 2018-03-08 Glenmark Pharmaceuticals S.A. Dérivés de 1,2,3-benzotriazole en tant que modulateurs de ror gamma t
US10005731B2 (en) 2012-12-06 2018-06-26 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2018116285A1 (fr) 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Dérivés de morpholine substitués en tant que modulateurs de ror gamma
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
WO2018123918A1 (fr) * 2016-12-26 2018-07-05 科研製薬株式会社 Dérivé de pyrazole et médicament le contenant
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN108610301A (zh) * 2016-12-12 2018-10-02 中山大学 一类手性芳杂胺类衍生物及其合成方法和应用
WO2018185675A1 (fr) 2017-04-04 2018-10-11 Glenmark Pharmaceuticals S.A. Analogues d'oxoazétidine substitués en tant que modulateurs de ror gamma
CN109081794A (zh) * 2018-09-28 2018-12-25 吉首大学 N-芳乙酰基氨基硫脲类尿素酶抑制剂及其制法和用途
US10189775B2 (en) 2015-08-28 2019-01-29 Glenmark Pharmaceuticals S.A. Carbocyclic compounds as ROR gamma modulators
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
RU2727698C2 (ru) * 2015-06-05 2020-07-23 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА (RORγ)
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US11229636B2 (en) 2015-05-15 2022-01-25 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ROR gamma modulators
WO2022023772A1 (fr) 2020-07-31 2022-02-03 AdoRx Therapeutics Limited Composés antagonistes
WO2023144559A1 (fr) 2022-01-28 2023-08-03 AdoRx Therapeutics Limited Antagoniste des récepteurs de l'adénosine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092146A2 (fr) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc Acides phenylalcanoiques substitues
WO2008057862A2 (fr) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092146A2 (fr) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc Acides phenylalcanoiques substitues
WO2008057862A2 (fr) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019626A1 (fr) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et procédés
WO2013029338A1 (fr) * 2011-09-01 2013-03-07 Glaxo Group Limited Nouveaux composés
WO2013064231A1 (fr) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013079223A1 (fr) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolocarboxamides en tant que modulateurs de l'activité d'un récepteur orphelin gamma (rorϒ, nr1f3) apparenté au récepteur nucléaire orphelin rar et destinés au traitement de maladies inflammatoires chroniques et auto-immunes
US10301272B2 (en) 2012-05-31 2019-05-28 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]
WO2013178362A1 (fr) 2012-05-31 2013-12-05 Phenex Pharmaceuticals Ag Thiazoles substitués par carboxamide ou sulfonamide et dérivés apparentés en tant que modulateurs du récepteur nucléaire orphelin ror[gamma]
EA027953B1 (ru) * 2012-08-09 2017-09-29 Фенекс Фармасьютикалз Аг АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
CN104603105B (zh) * 2012-08-09 2017-09-08 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节剂的甲酰胺或磺酰胺取代的含氮5元杂环
WO2014023367A1 (fr) 2012-08-09 2014-02-13 Phenex Pharmaceuticals Ag Hétérocycles à 5 chaînons contenant de l'azote substitués par carboxamide ou sulfonamide en tant que modulateurs pour le récepteur nucléaire orphelin ror gamma
EP3118189A1 (fr) 2012-08-09 2017-01-18 Phenex Pharmaceuticals AG Azote substitue de carboxamide ou sulfonamide contenant des heterocycles a 5 chainons en tant que modulateurs de recepteur nucleaire orphelin gamma ror
CN104603105A (zh) * 2012-08-09 2015-05-06 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节剂的甲酰胺或磺酰胺取代的含氮5元杂环
KR101732973B1 (ko) 2012-08-09 2017-05-08 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 질소-함유 5-원자 헤테로고리
TWI488839B (zh) * 2012-08-09 2015-06-21 Phenex Pharmaceuticals Ag 作爲孤兒核受體ＲＯＲγ調節物之經甲醯胺或磺醯胺取代之含氮５員雜環
US9458104B2 (en) 2012-08-09 2016-10-04 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ
AU2013301914B2 (en) * 2012-08-09 2016-08-18 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR gamma
NO344067B1 (en) * 2012-08-09 2019-08-26 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR gamma
WO2014062938A1 (fr) * 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Modulateurs du récepteur gamma orphelin associé aux rétinoïdes (rory)
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
US10005731B2 (en) 2012-12-06 2018-06-26 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2013171729A2 (fr) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt
WO2013171729A3 (fr) * 2013-01-08 2014-02-06 Glenmark Pharmaceuticals S.A. Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2975031A4 (fr) * 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2014179564A1 (fr) * 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Inhibiteurs du ror-gamma à base de thiazalopyrrolidine
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11053262B2 (en) 2013-07-03 2021-07-06 Takeda Pharmaceutical Company Limited Heterocyclic amide compounds having RORyT inhibitory action
US11851449B2 (en) 2013-07-03 2023-12-26 Takeda Pharmaceutical Company Limited Heterocyclic amide compounds having an RORvt inhibitory action
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
WO2015052675A1 (fr) * 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Utilisation de composés substitués dihydro-benzimidazole comme modulateurs du ror gamma
WO2015087234A1 (fr) 2013-12-10 2015-06-18 Glenmark Pharmaceuticals S.A. Analogues de l'indole héteroaryle bicyclique utiles en tant que modulateurs de gamma ror
US9682977B2 (en) 2013-12-10 2017-06-20 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl indole analogues useful as ROR gamma modulators
US9624217B2 (en) 2014-02-03 2017-04-18 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10807980B2 (en) 2014-02-03 2020-10-20 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10047085B2 (en) 2014-02-03 2018-08-14 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2015139619A1 (fr) * 2014-03-18 2015-09-24 北京韩美药品有限公司 Composé servant de modulateur rorγ
CN104926733A (zh) * 2014-03-18 2015-09-23 北京韩美药品有限公司 作为RORγ调节剂的化合物
CN104926733B (zh) * 2014-03-18 2019-05-10 北京韩美药品有限公司 作为RORγ调节剂的化合物
WO2015159233A1 (fr) 2014-04-16 2015-10-22 Glenmark Pharmaceuticals S.A. Composés éther d'aryle et éther d'hétéroaryle en tant que modulateurs de ror gamma
US9718817B2 (en) 2014-04-16 2017-08-01 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ROR gamma modulators
US9868724B2 (en) 2014-05-28 2018-01-16 Glaxosmithkline Intellectual Property Development Limited Compounds
US9902735B2 (en) 2014-05-28 2018-02-27 Glaxosmithkline Intellectual Property Development Limited Heteroaryl substituted compounds as RORγ inhibitors
US9902715B2 (en) 2014-05-28 2018-02-27 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015198232A1 (fr) 2014-06-25 2015-12-30 Piramal Enterprises Limited Composés de triterpène fusionnés et utilisations de ceux-ci
US10105373B2 (en) 2014-06-25 2018-10-23 Piramal Enterprises Limited Fused triterpene compounds and uses thereof
US10087184B2 (en) 2014-10-14 2018-10-02 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of RORγ
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10959984B2 (en) 2015-03-12 2021-03-30 The Regents Of The University Of California Methods for treating cancer with RORγ inhibitors
WO2016145298A1 (fr) 2015-03-12 2016-09-15 The Regents Of The University Of California Méthodes de traitement du cancer par des inhibiteurs de ror gamma
US11229636B2 (en) 2015-05-15 2022-01-25 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ROR gamma modulators
WO2016193894A1 (fr) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Traitement de troubles respiratoires au moyen d'inhibiteurs ror-gamma
US9855229B2 (en) 2015-05-29 2018-01-02 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ROR-gamma inhibitors
EP3101008A1 (fr) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
RU2727191C2 (ru) * 2015-06-05 2020-07-21 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА(RORγ)
WO2016193470A1 (fr) * 2015-06-05 2016-12-08 Lead Pharma Cel Models Ip B.V. Modulateurs de ror gamma (rory)
CN108430973B (zh) * 2015-06-05 2021-09-21 领先制药控股公司 RORγ调节剂
US10259782B2 (en) 2015-06-05 2019-04-16 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators
CN108430973A (zh) * 2015-06-05 2018-08-21 领先制药控股公司 RORγ调节剂
JP2018518481A (ja) * 2015-06-05 2018-07-12 リード ファーマ ホールディング ビー．ブイ． ＲＯＲガンマ（ＲＯＲγ）モジュレーター
RU2727698C2 (ru) * 2015-06-05 2020-07-23 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА (RORγ)
WO2017021879A1 (fr) 2015-08-03 2017-02-09 Glenmark Pharmaceuticals S.A. Nouveaux composés utilisés en tant que modulateurs de ror gamma
US10988467B2 (en) 2015-08-03 2021-04-27 Glenmark Pharmaceuticals S.A. Compounds as ROR gamma modulators
US9975887B2 (en) 2015-08-03 2018-05-22 Glenmark Pharmaceuticals S.A. Compounds as ROR gamma modulators
US10344024B2 (en) 2015-08-03 2019-07-09 Glenmark Pharmaceuticals S.A. Compounds as ROR gamma modulators
EP3686187A1 (fr) 2015-08-03 2020-07-29 Glenmark Pharmaceuticals S.A. Procédé de préparation des modulateurs de ror gamma
US10829448B2 (en) 2015-08-05 2020-11-10 Vitae Pharmaceuticals, Llc Substituted benzoimidazoles as modulators of ROR-γ
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10189775B2 (en) 2015-08-28 2019-01-29 Glenmark Pharmaceuticals S.A. Carbocyclic compounds as ROR gamma modulators
US10336688B2 (en) 2015-08-28 2019-07-02 Glenmark Pharmaceuticals S.A. Carbocyclic compounds as ROR gamma modulators
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11453644B1 (en) 2015-12-15 2022-09-27 Astrazeneca, Ab Compounds
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
US10526286B2 (en) 2015-12-15 2020-01-07 Astrazeneca Ab Compounds
US10988445B2 (en) 2015-12-15 2021-04-27 Astrazeneca Ab Compounds
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2018011747A1 (fr) 2016-07-14 2018-01-18 Cadila Healthcare Limited Composés polycycliques en tant que modulateurs de ror-gamma
WO2018011746A1 (fr) 2016-07-14 2018-01-18 Cadila Healthcare Limited Dérivés de cyclopropyle en tant que modulateurs de ror-gamma
WO2018042342A1 (fr) 2016-08-30 2018-03-08 Glenmark Pharmaceuticals S.A. Dérivés de 1,2,3-benzotriazole en tant que modulateurs de ror gamma t
CN108610301A (zh) * 2016-12-12 2018-10-02 中山大学 一类手性芳杂胺类衍生物及其合成方法和应用
CN108610301B (zh) * 2016-12-12 2021-08-31 中山大学 一类手性芳杂胺类衍生物及其合成方法和应用
WO2018116285A1 (fr) 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Dérivés de morpholine substitués en tant que modulateurs de ror gamma
WO2018123918A1 (fr) * 2016-12-26 2018-07-05 科研製薬株式会社 Dérivé de pyrazole et médicament le contenant
WO2018185675A1 (fr) 2017-04-04 2018-10-11 Glenmark Pharmaceuticals S.A. Analogues d'oxoazétidine substitués en tant que modulateurs de ror gamma
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
CN109081794A (zh) * 2018-09-28 2018-12-25 吉首大学 N-芳乙酰基氨基硫脲类尿素酶抑制剂及其制法和用途
WO2022023772A1 (fr) 2020-07-31 2022-02-03 AdoRx Therapeutics Limited Composés antagonistes
WO2023144559A1 (fr) 2022-01-28 2023-08-03 AdoRx Therapeutics Limited Antagoniste des récepteurs de l'adénosine

Similar Documents

Publication Publication Date Title
WO2012100734A1 (fr) Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma
WO2012027965A1 (fr) Nouveaux composés
WO2012028100A1 (fr) Nouveaux composés
WO2012100732A1 (fr) Modulateurs des récepteurs orphelins gamma apparentés au récepteur des rétinoïdes, composition les contenant et utilisations associées
US8481576B2 (en) Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
JP3884290B2 (ja) Ｈｐｐａｒアルファアクチベーターとしての置換オキサゾールおよびチアゾール誘導体
JP5225076B2 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
CA2587023C (fr) Derive d'acide carboxylique contenant un cycle thiazole et applications pharmaceutiques dudit derive
AU2016272018B2 (en) ROR gamma (RORy) modulators
JP2005509616A (ja) チロシンホスファターゼに対する有機硫黄阻害剤
WO2013029338A1 (fr) Nouveaux composés
JP3785397B2 (ja) ５員環化合物
CA2484233A1 (fr) Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete
CZ20033250A3 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
CA2694748A1 (fr) Inhibiteurs de canaux sodiques
US11911372B2 (en) Compounds
CA2605008A1 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
AU2005299829A1 (en) Pharmaceutical compositions
JP2004517100A (ja) ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
KR100707320B1 (ko) 신규 아미노티아졸 유도체, 이의 제조 방법 및 이를함유하는 제약 조성물
AU2003253364B2 (en) Thiazole derivatives
JP2003192591A (ja) ５員環化合物からなる医薬
AU2010316669B2 (en) Carboxy oxazole or thiazole compounds as DGAT - 1 inhibitors useful for the treatment of obesity
JP2006169257A (ja) ５員環化合物
KR20050056192A (ko) 싸이아졸 유도체

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739058

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12739058

Country of ref document: EP

Kind code of ref document: A1